Why Diagnosis Can Take Time — and Why You Are Not Alone
Last reviewed: 18 March 2026
Key points
- Long diagnostic journeys are common in many chronic and rare conditions—not just aspergillosis.
- Delays do not mean your symptoms were not real or important.
- Diagnosis often becomes clear over time, as patterns develop.
- Many patients go through similar experiences before reaching answers.
- Specialist centres play an important role when conditions are complex.
You are not alone in this
One of the most important things to understand is this:
Long and difficult diagnostic journeys are common—especially in chronic or complex illness.
Many people living with conditions such as chronic pulmonary aspergillosis (CPA) or allergic bronchopulmonary aspergillosis (ABPA) describe months or years of symptoms before a clear diagnosis was made.
This experience, while frustrating, is not unusual—and it does not mean your care has failed.
This happens in many conditions
Aspergillosis is not unique in this respect.
Similar diagnostic journeys are seen in:
- chronic lung diseases
- autoimmune conditions
- rare infections
- conditions with overlapping symptoms (e.g. fatigue syndromes)
In all of these, the same pattern often occurs:
- early symptoms are non-specific
- common conditions are treated first
- tests may initially be normal
- the true pattern only becomes clear over time
Why time helps diagnosis
Although it can feel like delay, time often provides essential information.
Patterns emerge
- symptoms become more consistent
- flare-ups follow recognisable triggers
- response to treatment becomes clearer
Tests become more informative
- changes appear on imaging (e.g. CT scans)
- blood markers become more clearly abnormal
- microbiology results become more consistent
What was unclear early on can become much more visible later.
The turning point
Many patients describe a moment when things begin to change:
- symptoms no longer fit common conditions
- treatments stop working as expected
- a clinician recognises a pattern
This is often the point where less common diagnoses—including aspergillosis—are considered.
The role of specialist centres
Complex conditions are often best diagnosed in specialist centres with experience in that field.
In the UK, the National Aspergillosis Centre provides:
- expert multidisciplinary assessment
- access to specialist diagnostics
- experience in recognising patterns of disease
Referral to a specialist centre is often a key step in reaching a diagnosis.
The emotional impact
Long periods without answers can be deeply challenging.
Patients often describe:
- frustration and uncertainty
- feeling unheard or misunderstood
- loss of confidence in their own body
These reactions are entirely understandable.
Your experience is valid—even if the diagnosis took time to emerge.
Moving forward
Once a diagnosis is made, many patients feel a sense of relief—even if treatment is still needed.
A diagnosis provides:
- an explanation for symptoms
- a direction for treatment
- a clearer future plan
Even before diagnosis, it is important to remember:
You are still on a pathway—just not always a straight one.
Common questions
Does a long delay mean something was missed?
Not necessarily. Many conditions are only diagnosable once they have developed further.
Should I have been referred earlier?
Sometimes earlier referral is helpful, but it usually depends on how symptoms evolve over time.
Is this unique to aspergillosis?
No—this pattern is seen across many chronic and rare conditions.
Why Aspergillosis Is So Hard to Diagnose
Last reviewed: 18 March 2026
Key points
- Aspergillosis is often difficult to diagnose because its symptoms can look very similar to those of more common conditions.
- Diagnosis usually depends on several pieces of evidence being brought together, rather than one simple test.
- Doctors are trained to consider common conditions first, because this is usually the safest and most efficient approach.
- This approach works well for many patients, but it can delay recognition of conditions such as aspergillosis.
- Delays are often caused by the way healthcare systems are organised, not by lack of care or effort from individual clinicians.
- Patients can help by keeping a clear record of symptoms, tests, treatments, and how things have changed over time.
Why diagnosis can be difficult
Aspergillosis is not a single illness but a group of conditions caused by Aspergillus, a mould commonly found in the environment. These include:
- Allergic bronchopulmonary aspergillosis (ABPA)
- Chronic pulmonary aspergillosis (CPA)
- Other airway and colonisation-related conditions
Diagnosis usually depends on combining:
- symptoms over time
- CT scan findings
- blood tests (including immunological tests)
- sputum microbiology
- clinical history
There is rarely a single “yes or no” test, which is why diagnosis can take time.
What the patient journey often looks like
Early symptoms
Symptoms such as cough, breathlessness, fatigue, or sputum are common across many conditions including bronchiectasis, asthma, and infection.
Treatment for common conditions
Initial treatment often includes antibiotics, inhalers, or steroids. These are appropriate first steps based on clinical guidelines such as those from the British Thoracic Society (BTS).
Ongoing symptoms
When symptoms persist or return, further investigation is usually needed.
The turning point
At some stage, fungal disease may be considered and tests for Aspergillus are performed.
Why doctors tackle common conditions first
Why do doctors start with common conditions?
Doctors treat common diseases first, prioritizing efficiency, patient safety, and high-probability outcomes. This approach, considering the most likely diagnosis first, helps manage patient health efficiently and effecctively before investigating rare or complex conditions.
This approach is safe and effective for most people, but conditions like aspergillosis can sit outside these usual pathways.
Where delays can happen
Overlap of symptoms
Symptoms overlap with many conditions, including tuberculosis and lung cancer.
No single definitive test
Diagnosis often requires combining multiple test results rather than relying on one.
Gradual disease progression
Conditions such as CPA may evolve over months or years.
Multiple conditions
Patients may have more than one lung condition at the same time.
Why this is often about the system, not the individual doctor
Healthcare systems are designed to manage large numbers of patients efficiently and safely. This means prioritising common conditions first.
However, aspergillosis often requires specialist input. In the UK, this may include referral to the National Aspergillosis Centre, which provides expert assessment and management.
International guidance from organisations such as ESCMID (European Society of Clinical Microbiology and Infectious Diseases) also highlights the complexity of fungal diseases.
What patients can do
- Keep a record of symptoms and treatments
- Ask when diagnosis should be reviewed
- Discuss whether further tests are needed
- Use trusted information sources such as our diagnosis guide
A more balanced way to think about delay
Diagnosis is often not a single event but a process that unfolds over time.
The goal is to recognise patterns earlier and ensure patients who need specialist input are identified sooner.
Common questions
Why was I treated for other conditions first?
Because those conditions are more common and more likely.
Should I ask about aspergillosis?
Yes, especially if symptoms are persistent or unusual—but it should be part of a broader discussion.
When to seek medical advice
- Persistent or worsening symptoms
- Coughing up blood
- Unexplained weight loss
References and further reading
Nontuberculous Mycobacteria (NTM–MAC) and Aspergillosis
Why these infections sometimes occur together
Audience: Aspergillosis patients, carers, GPs and non-specialist clinicians
Some patients with Allergic Bronchopulmonary Aspergillosis (ABPA) may be investigated for nontuberculous mycobacteria (NTM), because airway damage from ABPA can increase susceptibility to other lung infections.
Key points
- Nontuberculous mycobacteria (NTM) are environmental bacteria that sometimes infect damaged lungs.
- The most common NTM causing lung disease is the Mycobacterium avium complex (MAC).
- NTM infection and aspergillosis often occur in the same patients because both thrive in damaged airways such as bronchiectasis or lung cavities.
- Some patients with ABPA are investigated for NTM because ABPA can lead to bronchiectasis and impaired mucus clearance.
- NTM infections usually grow very slowly, so treatment is sometimes monitored rather than started immediately.
- Treating NTM and aspergillosis together can be difficult because some NTM antibiotics interfere with antifungal medicines.
- Doctors usually treat the infection causing the most harm first while monitoring the other carefully.
Table of contents
- What are NTM?
- What is Mycobacterium avium complex (MAC)?
- Why NTM infections occur in some people
- What is bronchiectasis?
- Why patients with ABPA may be asked about NTM
- Why NTM and Aspergillus infections often occur together
- The lung infection cycle
- Chronic lung disease as a microbial ecosystem
- Why treatment can be complicated
- When treatment for NTM may be delayed
- How doctors balance treatment decisions
- NTM vs Aspergillosis – comparison table
- Common questions patients ask about NTM and Aspergillus
- When should patients seek medical advice?
- Reducing exposure to NTM in the environment
What are nontuberculous mycobacteria (NTM)?
Nontuberculous mycobacteria (NTM) are bacteria found naturally in the environment.
They live in:
- soil
- water
- dust
- plumbing systems
- shower heads and taps
Unlike tuberculosis, these bacteria are not normally spread between people.
Most people inhale them regularly without becoming ill. However, in some people with damaged lungs, these bacteria can establish a long-term lung infection.
What is Mycobacterium avium complex (MAC)?
The Mycobacterium avium complex (MAC) is the most common cause of NTM lung disease.
This group includes:
- Mycobacterium avium
- Mycobacterium intracellulare
MAC lung disease usually develops slowly over months or years.
Symptoms may include:
- chronic cough
- sputum production
- breathlessness
- fatigue
- weight loss
Because symptoms develop gradually, diagnosis can sometimes take time.
Why NTM infections occur in some people
NTM infections usually develop in people who already have structural lung disease.
Examples include:
- bronchiectasis
- chronic obstructive pulmonary disease (COPD)
- cystic fibrosis
- previous tuberculosis
- severe asthma
- aspergillosis
In these conditions, the lungs have damaged or widened airways, making it harder to clear mucus and microbes.
What is bronchiectasis?
Bronchiectasis is a condition where the airways become permanently widened and distorted.
In healthy lungs, mucus is cleared using:
- mucus movement
- tiny hair-like structures called cilia
- coughing
In bronchiectasis:
- mucus collects in the airways
- microbes become trapped
- infections become more likely
Bronchiectasis is common in patients with Allergic Bronchopulmonary Aspergillosis (ABPA) and other chronic lung diseases.
Why patients with ABPA may be asked about NTM
Some patients with Allergic Bronchopulmonary Aspergillosis (ABPA) are surprised when their doctors start investigating nontuberculous mycobacteria (NTM).
This usually happens because ABPA can lead to bronchiectasis, which increases the risk of other lung infections.
In ABPA:
- inflammation caused by allergic reactions to Aspergillus can damage the airways
- over time the airways may become widened and distorted, causing bronchiectasis
- mucus clearance becomes less effective
When mucus accumulates in the airways, microbes that are normally cleared from the lungs can sometimes persist. These may include:
- nontuberculous mycobacteria (NTM)
- Pseudomonas bacteria
- other organisms that affect bronchiectasis patients
For this reason, doctors sometimes test patients with ABPA for NTM if:
- CT scans show bronchiectasis or nodules
- sputum cultures repeatedly grow unusual organisms
- symptoms worsen without a clear explanation
Importantly, having ABPA does not mean you will develop NTM infection. Most patients with ABPA never develop NTM disease.
However, because the conditions share similar risk factors, doctors sometimes check for both.
Why NTM and Aspergillus infections often occur together
NTM bacteria and Aspergillus fungi both thrive in damaged lungs.
Three factors explain the overlap.
1. Damaged airways trap microbes
When airways are widened or distorted:
- mucus collects
- microbes are not cleared effectively
This allows organisms such as NTM and Aspergillus to persist.
2. Chronic infection causes further lung damage
NTM infection can lead to:
- inflammation
- worsening bronchiectasis
- lung nodules
- sometimes lung cavities
These cavities can then be colonised by Aspergillus, which may lead to chronic pulmonary aspergillosis (CPA).
3. Aspergillus can worsen structural damage
Once Aspergillus becomes established it can cause:
- inflammation
- enlargement of lung cavities
- worsening bronchiectasis
This further damage makes the lungs even more susceptible to infection.
The lung infection cycle
In many patients the relationship between bronchiectasis, NTM and Aspergillus becomes a cycle:
- Lung disease develops
- Bronchiectasis forms
- NTM infection establishes
- Lung damage worsens
- Aspergillus colonises damaged tissue
- Chronic aspergillosis develops
- Lung damage continues
At this stage the lungs may contain multiple organisms simultaneously.
Chronic lung disease as a microbial ecosystem
Doctors increasingly recognise that damaged lungs may contain several interacting microbes rather than a single infection.
Common organisms include:
- Mycobacterium avium complex (MAC)
- Aspergillus species
- Pseudomonas bacteria
- other organisms
For this reason clinicians sometimes describe chronic lung disease as a disturbed lung microbial ecosystem.
Why treatment can be complicated
NTM and aspergillosis treatments can interact.
Typical MAC treatment includes:
- azithromycin or clarithromycin
- ethambutol
- rifampicin
However rifampicin strongly reduces levels of antifungal drugs, including:
- itraconazole
- voriconazole
- posaconazole
These antifungals are commonly used to treat chronic pulmonary aspergillosis.
Because of this interaction, treating both infections at the same time can be challenging.
Other medicines that may interact with rifampicin
Rifampicin affects how the liver processes many medicines. This means it can reduce the effectiveness of several commonly used drugs, including some treatments for heart conditions, blood thinners, hormonal medicines, and certain antidepressants.
Because of this, doctors and pharmacists always review a patient’s medication list before starting rifampicin. Patients should tell their healthcare team about all medicines they take, including over-the-counter medicines, inhalers, and herbal supplements. In most cases, safe alternatives or dose adjustments can be used if needed.
When treatment for NTM may be delayed
Unlike many bacterial infections, MAC often progresses slowly.
Doctors sometimes monitor the infection before starting treatment. This approach is called active monitoring or watchful waiting.
Monitoring may include:
- CT scans
- sputum cultures
- lung function tests
- symptom assessment
Treatment may be delayed if:
- symptoms are mild
- CT scans are stable
- another condition requires more urgent treatment
For example, aspergillosis may be treated first if it is causing the main symptoms or lung damage.
How doctors balance treatment decisions
When both infections are present, clinicians try to identify which infection is currently causing the most harm.
Doctors consider:
Symptoms
- worsening cough
- breathlessness
- fatigue
- weight loss
- haemoptysis (coughing blood)
CT scan findings
- enlarging cavities
- fungal balls
- nodules typical of NTM disease
- worsening bronchiectasis
Laboratory results
- sputum cultures for NTM
- Aspergillus blood tests, such as Aspergillus IgG
If one infection clearly explains the patient’s symptoms, that infection usually becomes the treatment priority.
Treatment plans may then change over time as the balance of disease changes.
NTM vs Aspergillosis – What’s the difference?
| Feature | NTM (MAC) Lung Disease | Aspergillosis |
|---|---|---|
| Type of organism | Bacteria | Fungus |
| Source | Soil, water, plumbing | Airborne fungal spores |
| Spread between people | Rare | Does not spread |
| Typical speed | Slow, chronic infection | Variable |
| Typical CT findings | Nodules, bronchiectasis, cavities | Cavities, fungal balls, airway inflammation |
| Treatment | Long antibiotic courses, often 12–18 months | Antifungal medicines |
| Drug interaction issues | Rifampicin interferes with antifungals | Antifungal levels can be reduced by rifampicin |
Common questions patients ask about NTM and Aspergillus
If MAC grows slowly, why treat it?
Although MAC grows slowly, it can still cause progressive lung damage over time.
Treatment is usually recommended if there is:
- worsening symptoms
- declining lung function
- progressive CT scan changes
Can NTM be present without causing disease?
Yes. Some people have NTM colonisation without active infection.
Doctors diagnose NTM lung disease only when symptoms, imaging findings and repeated cultures all support the diagnosis.
Why do NTM and Aspergillus often occur together?
Both organisms tend to grow in damaged airways, especially where bronchiectasis is present and mucus clearance is poor.
Will both infections always be treated?
Not necessarily. Doctors often treat the infection causing the most immediate problem while monitoring the other.
Does NTM mean my aspergillosis is worsening?
Not necessarily. Both infections occur in damaged lungs, so they may simply share the same environment.
Can NTM lead to aspergillosis?
Sometimes. If NTM infection causes lung cavities or worsening bronchiectasis, these damaged areas may later become colonised by Aspergillus.
Should I worry if my doctor decides not to treat NTM immediately?
Not necessarily. Because MAC often progresses slowly, doctors sometimes choose active monitoring rather than immediate treatment.
When should patients seek medical advice?
People living with aspergillosis, bronchiectasis or NTM infection often have ongoing symptoms such as cough and sputum production. These symptoms may fluctuate and do not always mean the disease is worsening.
However, certain changes should prompt medical review.
Seek medical advice if you notice worsening breathing symptoms
- increasing breathlessness
- a significant increase in cough
- a noticeable increase in sputum production
- sputum becoming thicker, darker or foul-smelling
These symptoms may indicate:
- bacterial infection
- worsening bronchiectasis
- progression of NTM infection
- worsening aspergillosis
Coughing up blood (haemoptysis)
Haemoptysis can occur in both bronchiectasis and aspergillosis.
Seek medical advice if:
- bleeding increases
- blood appears repeatedly
- there is more than a small amount of blood
- bleeding occurs suddenly with breathlessness
Large amounts of blood should be treated as a medical emergency.
Unexplained weight loss or increasing fatigue
Persistent or worsening:
- weight loss
- fatigue
- loss of appetite
may indicate:
- progressive infection
- increasing inflammation
- advancing NTM disease
Fever or feeling unwell
New symptoms such as:
- fever
- chills
- chest discomfort
- feeling generally unwell
may suggest a new infection, such as a bacterial chest infection, which may require treatment.
Rapid change in symptoms
Seek medical advice if you experience:
- sudden worsening breathlessness
- significant chest pain
- new wheezing
- severe fatigue developing quickly
Symptoms that may remain stable
Many people with chronic lung disease experience symptoms that remain relatively stable for long periods, including:
- a chronic cough
- daily sputum production
- mild breathlessness
- intermittent fatigue
Doctors monitor these symptoms over time using:
- CT scans
- sputum cultures
- lung function tests
These investigations help clinicians determine whether infections such as NTM or Aspergillus are stable or progressing.
Reducing exposure to NTM in the environment
Patients with bronchiectasis, ABPA, or other chronic lung diseases sometimes ask whether they should try to avoid environmental exposure to nontuberculous mycobacteria (NTM).
NTM are very common in the natural environment and cannot be completely avoided. They are found in:
- soil and compost
- garden dust
- natural water sources
- tap water and plumbing systems
- showerheads
- hot tubs and spa pools
For most people, the goal is sensible risk reduction rather than strict avoidance. Major lifestyle restrictions are usually not necessary.
Water exposure
NTM can grow in biofilms inside plumbing systems, including showerheads. Small amounts of bacteria may become airborne when water is aerosolised.
Some simple precautions may help reduce exposure:
- avoid frequent use of hot tubs or spa pools
- allow taps or showers to run briefly if they have not been used for several days
- clean showerheads periodically to remove biofilm and limescale
Normal showering and bathing are considered safe for most patients.
NTM infection occurs when bacteria are inhaled into the lungs rather than swallowed. Drinking ordinary tap water is therefore considered safe for most people, and patients are not usually advised to avoid tap water for drinking.
Gardening and soil exposure
NTM bacteria are often present in soil and compost. Gardening can still be enjoyed safely with a few sensible precautions.
- wear gloves when gardening
- avoid inhaling dust from dry compost or soil
- dampen compost before handling to reduce dust
- wash hands after gardening
For people with bronchiectasis or NTM disease, wearing a mask during dusty gardening activities may help reduce inhalation of soil particles.
Reducing dust exposure
Activities that generate dust can increase inhalation of environmental microbes.
Helpful precautions include:
- avoiding sweeping very dusty areas indoors
- ventilating indoor spaces
- wearing a mask during dusty tasks such as handling compost or dry soil
Cleaning showerheads
Cleaning showerheads periodically can help remove limescale and biofilms where microbes may grow.
A simple method is:
- Remove the showerhead if possible.
- Soak it in white vinegar for about 30–60 minutes.
- Gently scrub the spray holes with a small brush.
- Rinse thoroughly.
- Run hot water for 30–60 seconds before use.
If the showerhead cannot be removed, a plastic bag filled with vinegar can be tied around the head so that it soaks.
Cleaning every 1–3 months is usually sufficient.
What is usually not necessary
Experts generally do not recommend major lifestyle changes to avoid NTM exposure. In most cases it is not necessary to:
- avoid showers
- avoid gardening completely
- install specialised water filtration systems
These activities are important for quality of life and general health, and evidence that strict avoidance prevents NTM disease is limited.
The most important protection
For patients with ABPA, bronchiectasis or aspergillosis, the most important protective measures remain:
- good airway clearance
- regular medical monitoring
- prompt treatment of infections
- maintaining overall lung health
Reducing environmental exposure may help slightly, but good management of lung disease remains the most important factor.
Key message
When NTM and Aspergillus infections occur together, treatment decisions focus on which infection is currently causing the most damage, while avoiding harmful drug interactions.
For patients with ABPA, one reason NTM may be discussed is that ABPA can lead to bronchiectasis and impaired mucus clearance, which can make other infections more likely.
Many patients live with these conditions for years with careful monitoring and specialist management.
Author: National Aspergillosis Centre Patient Information Team
Last reviewed: March 2026
Travelling with Aspergillosis: A Comprehensive Guide to Safe and Stable Travel
This guide is for people living with:
- Chronic Pulmonary Aspergillosis (CPA)
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Severe asthma (including fungal sensitisation)
- Bronchiectasis
- Fibrotic or structurally abnormal lung disease
Most people with stable disease can travel successfully. The goal is not restriction — it is risk reduction through preparation, environmental awareness, and early action if symptoms change.
Contents
- 1. Understanding Travel Risk in Aspergillosis
- 2. Coordinating With Your Medical Team
- 3. Assessing Stability Before Travel
- 4. Choosing a Destination: Environmental Determinants
- 5. Regional Risk Patterns Explained
- 6. Air Pollution & AQI Monitoring
- 7. Heat, Humidity & Hydration Physiology
- 8. Travel Insurance & Disclosure
- 9. Medication Planning & Contingency Prescriptions
- 10. Specific Considerations for Azole Antifungals
- 11. Air Travel: Physiology & Fit-to-Fly
- 12. Cabin Dryness & Post-Flight Irritation
- 13. Travelling with Oxygen
- 14. Accommodation Risk Reduction
- 15. High-Spore & Dust Exposure Environments
- 16. Infection Prevention
- 17. Haemoptysis Planning
- 18. Red Flag Symptoms
- 19. Advanced Planning Checklist
1. Understanding Travel Risk in Aspergillosis
Travel risk arises from four domains:
- Structural lung vulnerability (cavities, fibrosis, bronchiectasis)
- Inflammatory instability (ABPA activity, asthma control)
- Environmental exposure (humidity, dust, pollution)
- Healthcare accessibility (if deterioration occurs)
Travel is usually safe when disease is stable and exposures are predictable.
2. Coordinating With Your Medical Team
Respiratory Clinic
- Review recent imaging (particularly in CPA)
- Assess haemoptysis history
- Consider fit-to-fly testing if oxygen saturation borderline
- Discuss standby rescue medication
GP
- Ensure medication supply exceeds travel duration
- Provide updated medication summary
- Support vaccination review
- Assist with insurance documentation
3. Assessing Stability Before Travel
Delay travel if within 4–6 weeks of:
- Significant haemoptysis
- Escalating breathlessness
- Recent hospital admission
- New antifungal initiation
Stable inflammatory markers and symptom plateau are reassuring.
4. Choosing a Destination: Environmental Determinants
Key determinants:
- Humidity: promotes indoor mould growth
- Flood history: water damage increases fungal load
- Air pollution: triggers bronchospasm
- Dust burden: irritates inflamed airways
- Healthcare infrastructure: safety net if unwell
5. Regional Risk Patterns Explained
Lower Overall Respiratory Stress
- Scandinavia
- New Zealand
- Canada (outside wildfire season)
Cooler climates limit mould growth; strong building codes reduce damp housing.
Moderate Risk
- Mediterranean Europe
Generally safe when stable; monitor wildfire smoke and heat stress.
Higher Respiratory Stress
- Tropical monsoon climates
- Flood-prone regions
- Highly polluted megacities
- Dust storm zones
Humidity increases fungal proliferation; particulate pollution worsens airway inflammation.
6. Air Pollution & AQI Monitoring
Air pollution can exacerbate cough, bronchospasm, breathlessness and fatigue in people with chronic lung disease. In some urban environments, pollution may pose a greater day-to-day risk than fungal exposure.
The most widely used measure of air quality is the Air Quality Index (AQI), which combines several pollutants into a single score.
Key Pollutants That Matter in Lung Disease
- PM2.5 – fine particulate matter small enough to penetrate deep into the lungs
- PM10 – larger inhalable particles
- Ozone (O₃) – irritates airways, especially in heat
- Nitrogen dioxide (NO₂) – associated with traffic pollution
PM2.5 is particularly important in aspergillosis and severe asthma because it can:
- Trigger airway inflammation
- Increase mucus production
- Worsen bronchospasm
- Reduce exercise tolerance
Reliable Air Quality Monitoring Resources
These sites provide real-time data and forecasts:
- World Air Quality Index (WAQI)
https://waqi.info
Interactive global map with live AQI data for cities worldwide. - IQAir (AirVisual)
https://www.iqair.com
Detailed pollutant breakdowns, 7-day forecasts and wildfire smoke tracking. - UK Daily Air Quality Index (DEFRA)
https://uk-air.defra.gov.uk
Official UK monitoring network with health advice bands.
These platforms also offer mobile apps, which are useful for checking conditions while travelling.
How to Interpret AQI in Practical Terms
| AQI | Category | Practical Advice for Lung Conditions |
|---|---|---|
| 0–50 | Good | Ideal conditions for outdoor activity |
| 51–100 | Moderate | Usually safe; monitor symptoms |
| 101–150 | Unhealthy for sensitive groups | Reduce strenuous outdoor activity; consider indoor plans |
| 151–200 | Unhealthy | Limit time outdoors; avoid exertion |
| 200+ | Very Unhealthy/Hazardous | Stay indoors with filtered air if possible |
For many patients with CPA, ABPA or severe asthma, an AQI above 100 warrants caution. Above 150, limiting outdoor exposure is advisable.
Wildfire Smoke
Wildfire smoke contains high concentrations of PM2.5 and organic particulates. Even patients who are stable at home may experience:
- Increased cough
- Chest tightness
- Increased sputum production
- Fatigue
If travelling during wildfire season:
- Check AQI daily
- Plan indoor activities when levels are elevated
- Use air-conditioned or filtered indoor environments
- Carry rescue inhalers
Urban Pollution vs Rural Dust
Urban areas are more affected by traffic-related pollutants (NO₂, PM2.5), while rural or desert areas may present dust exposure. Both can aggravate inflamed airways.
The risk is cumulative. Short exposure is usually tolerated; prolonged high-level exposure increases the likelihood of symptom flare.
Key principle: checking AQI before and during travel is one of the simplest and most effective risk-reduction steps for people with chronic lung disease.
7. Heat, Humidity & Hydration Physiology
Hot climates place additional physiological stress on people with chronic lung disease.
Why Heat Matters
In warm environments, the body increases sweating and respiratory water loss to regulate temperature. This leads to:
- Increased insensible fluid loss (fluid lost through breathing and skin)
- Reduced plasma volume if intake is inadequate
- Thickening of airway secretions
In bronchiectasis and chronic pulmonary aspergillosis (CPA), mucus clearance is already impaired. Dehydration increases mucus viscosity, making sputum:
- Harder to expectorate
- More likely to stagnate in damaged airways
- Potentially more prone to secondary infection
Patients may notice thicker sputum, increased cough, or chest tightness in hot weather.
Humidity: Helpful or Harmful?
Humidity has mixed effects:
- Moderate humidity can help prevent airway drying.
- High humidity can increase environmental mould growth, particularly indoors if ventilation is poor.
In tropical or monsoon climates, poorly ventilated buildings may have higher fungal spore burdens due to damp conditions.
Heat, Fatigue & Breathlessness
Heat increases cardiovascular demand. The heart works harder to dissipate heat, which can:
- Increase perceived breathlessness
- Increase fatigue
- Reduce exercise tolerance
This does not necessarily indicate worsening lung disease — but it can feel similar.
Hydration Strategy
Practical recommendations:
- Begin hydrating the day before travel
- Drink fluids regularly rather than waiting for thirst
- Aim for pale straw-coloured urine
- Increase intake during flights and hot excursions
Limit:
- Excess alcohol (diuretic effect)
- High caffeine intake
Additional Practical Measures
- Plan outdoor activity early morning or evening
- Rest during peak heat (midday)
- Use air-conditioned environments when available
- Continue airway clearance routines while travelling
Key principle: in chronic lung disease, hydration supports mucus clearance and reduces avoidable exacerbation risk during hot weather.
8. Travel Insurance & Full Medical Disclosure
Travel insurance is not a formality — it is a critical safety net for people with chronic lung disease.
When purchasing insurance, you must declare all pre-existing medical conditions. This typically includes:
- Chronic Pulmonary Aspergillosis (CPA)
- Allergic Bronchopulmonary Aspergillosis (ABPA)
- Severe asthma
- Bronchiectasis
- Pulmonary fibrosis
- Long-term steroid therapy
- Adrenal insufficiency (if present)
- Oxygen use (even if only occasional)
Why Full Disclosure Matters
If you fail to declare a relevant condition, the insurer may:
- Refuse to cover medical treatment abroad
- Decline repatriation costs
- Refuse to reimburse cancelled flights or accommodation
- Invalidate the entire policy
This applies even if the emergency appears unrelated. Insurers may review your full medical history during a claim.
What Insurers Typically Ask
You may be asked:
- Have you been hospitalised in the past 12 months?
- Have you had medication changes recently?
- Have you had haemoptysis?
- Are you awaiting tests or investigations?
- Are you on long-term steroids?
Answer these questions carefully and honestly.
Policies and Stability
Some insurers will decline cover if:
- You have been hospitalised recently
- You are awaiting investigations
- Your condition is considered unstable
This is another reason to travel during a period of clinical stability.
European Travel (UK Patients)
If travelling within Europe, ensure you carry:
- Your GHIC (Global Health Insurance Card)
However, GHIC does not replace travel insurance. It may not cover:
- Private healthcare
- Mountain rescue
- Repatriation to the UK
Practical Tips
- Purchase insurance as soon as you book travel
- Keep written confirmation of declared conditions
- Carry the insurer’s emergency contact number with you
- Inform the insurer early if you require hospital care abroad
In summary: full disclosure protects you. Insurance is only effective if the insurer understands your medical background from the outset.
9. Medication Planning & Contingency Prescriptions
- Carry 1–2 weeks extra supply
- Bring medications in original packaging
- Carry clinic letter
- Consider written rescue plan
10. Specific Considerations for Azole Antifungals
Azoles have significant drug–drug interactions.
- Inform any clinician abroad you are taking an azole
- Avoid grapefruit
- Be aware of sun sensitivity (voriconazole)
- Take itraconazole with food
11. Air Travel: What Actually Happens in the Cabin?
Commercial aircraft cabins are pressurised to simulate an altitude of approximately 6,000–8,000 feet (1,800–2,400 metres).
This means the partial pressure of oxygen is lower than at sea level. For healthy individuals this causes only a small drop in oxygen saturation (typically 3–4%).
Are Most People with Aspergillosis OK to Fly?
Yes — most stable patients fly without difficulty.
People who are:
- Clinically stable
- Not oxygen-dependent
- Without recent haemoptysis
- With resting oxygen saturations ≥95%
generally tolerate commercial flights well, including medium and long-haul travel.
Many patients report anxiety before their first flight after diagnosis, but in stable disease, significant problems are uncommon.
Who Should Consider Fit-to-Fly Testing?
Assessment may be appropriate if you have:
- Resting oxygen saturation consistently below 95%
- Advanced pulmonary fibrosis
- Extensive cavitation
- Significant breathlessness at minimal exertion
- Recent clinical deterioration
The test commonly used is a Hypoxic Challenge Test (HCT), which simulates cabin oxygen conditions to determine whether supplemental oxygen is required during flight.
Where would I have a Hypoxic Challenge Test (HCT)?
In the UK, a Hypoxic Challenge Test is usually arranged through a hospital respiratory physiology department.
You cannot book this test directly. It must be requested by:
- Your respiratory consultant or clinic, or
- Occasionally your GP (who would refer you to a hospital service)
The test is typically performed in:
- A hospital lung function laboratory
- A respiratory physiology unit
- A specialist respiratory centre
During the test, you breathe a gas mixture containing a lower oxygen concentration (usually around 15%) to simulate aircraft cabin conditions. Your oxygen saturation is monitored continuously. If levels fall below safe thresholds, in-flight oxygen may be recommended.
Do Most People Need This Test?
No. Many stable patients with normal resting oxygen saturation (typically ≥95%) do not require hypoxic challenge testing.
The test is generally considered if you:
- Have resting oxygen saturation below 95%
- Have advanced pulmonary fibrosis
- Are already using oxygen
- Have significant exertional desaturation
If you are unsure, ask your respiratory team whether assessment is appropriate for you.
Symptoms During Flight: What Is Normal?
Mild symptoms that can occur in stable patients include:
- Slight increase in breathlessness on walking the aisle
- Fatigue
- Dry cough (often due to low humidity)
These are usually temporary and not dangerous.
Severe symptoms (marked breathlessness at rest, chest pain, dizziness, confusion) are uncommon and require crew notification.
Anxiety vs Physiological Breathlessness
It is very common for people with chronic lung disease to experience heightened awareness of their breathing during flights. The enclosed environment, reduced cabin pressure and awareness of altitude can all increase anxiety.
Anxiety-related breathlessness typically presents as:
- A sensation of not getting a “satisfying” breath
- Chest tightness without wheeze
- Rapid breathing (hyperventilation)
- Tingling in fingers or lips
- Light-headedness
Hyperventilation lowers carbon dioxide levels in the blood. This can cause dizziness, tingling and a feeling of air hunger — even when oxygen levels are normal.
Physiological hypoxia (true low oxygen levels) is less common in stable patients who have been assessed as fit to fly. When it occurs, it is more likely in those with advanced fibrosis, low baseline oxygen saturations, or recent instability.
Features more suggestive of physiological compromise include:
- Persistent breathlessness at rest
- Worsening cyanosis (bluish lips or fingers)
- Marked fatigue or confusion
- Objective low oxygen saturation if measured
For patients who have undergone fit-to-fly assessment and been cleared to travel, significant in-flight hypoxia is uncommon.
Practical Strategies
- Use slow, paced breathing (e.g. inhale for 4 seconds, exhale for 6 seconds)
- Focus on extended exhalation to reduce hyperventilation
- Keep shoulders relaxed and posture upright
- Avoid repeatedly “checking” your breathing
- Remind yourself that mild symptoms are common and expected
Understanding the difference between anxiety-related breathlessness and true hypoxia can significantly reduce distress during flight.
Deep Vein Thrombosis (DVT) Risk
Chronic lung disease does not automatically increase DVT risk, but long-haul immobility does.
General advice:
- Move legs regularly
- Stay hydrated
- Avoid excess alcohol
12. Cabin Dryness & Post-Flight Airway Irritation
Cabin humidity is typically 10–20% (normal indoor comfort is 40–60%).
Low humidity can:
- Dry airway lining
- Reduce mucociliary clearance
- Thicken secretions
- Trigger cough or mild bronchospasm
This is often why people feel they have “caught a cold” the day after flying. In most cases, it is airway irritation rather than infection.
How to Reduce Dryness Effects
- Hydrate well before and during flight
- Limit alcohol and caffeine
- Use isotonic saline nasal spray
- Continue preventer inhalers
- Keep rescue inhaler accessible
- Avoid direct overhead air vents blowing onto your face
- Consider mask use — masks increase humidity of inhaled air
Symptoms typically settle within 24–48 hours.
When to Seek Advice After Flying
Seek medical advice if you develop:
- Progressively worsening breathlessness
- Persistent fever
- Significant haemoptysis
- Chest pain
In stable patients, serious in-flight deterioration is uncommon.
12. Cabin Dryness & Post-Flight Irritation
Cabin humidity is 10–20%.
Dry air:
- Reduces mucociliary clearance
- Thickens secretions
- Triggers cough
- Irritates airways
Hydration and saline sprays reduce symptoms. Post-flight irritation commonly lasts 24–48 hours and does not necessarily indicate infection.
13. Travelling with Oxygen
Confirm airline device approval and battery duration. Plan well in advance.
14. Accommodation Risk Reduction
Request:
- Hard flooring
- No damp odour
- No renovation dust
- Pet-free rooms
Chains Often Reported as Allergy-Conscious
- Hyatt
- Hilton
- Marriott
- Scandic
- Premier Inn
Newer business hotels often have better HVAC filtration.
15. High-Spore & Dust Exposure Environments
- Compost handling
- Construction sites
- Flood-damaged buildings
- Agricultural dust
Avoid heavy inhalation exposure.
16. Infection Prevention
- Hand hygiene
- Avoid close contact with visibly unwell individuals
- Maintain vaccination schedule
17. Haemoptysis Planning
If you have a history of haemoptysis:
- Know your previous pattern
- Carry clinic contact details
- Seek urgent care if volume increases significantly
18. Red Flag Symptoms
- Increasing breathlessness
- New or worsening haemoptysis
- Persistent fever
- Severe chest pain
19. Advanced Planning Checklist
- Travel when stable
- Plan with GP and respiratory clinic
- Carry documentation
- Monitor AQI
- Hydrate on flights
- Avoid damp & heavy dust
- Know red flags
With preparation, most people with stable aspergillosis travel safely and successfully.
Isavuconazole in Aspergillosis
A balanced guide for patients and clinicians
Isavuconazole (given as the prodrug isavuconazonium sulfate) is a newer broad-spectrum triazole antifungal used in:
-
Chronic pulmonary aspergillosis (CPA)
-
Invasive aspergillosis
-
Patients who cannot tolerate other azoles
-
Selected refractory Allergic bronchopulmonary aspergillosis (ABPA) cases
It is available as oral capsules and intravenous (IV) formulation and is often chosen for its favourable tolerability profile.
1️⃣ What Isavuconazole Does
Like other azoles, isavuconazole inhibits fungal CYP51 (14-α-demethylase), blocking ergosterol synthesis and impairing fungal cell membrane formation.
It:
-
Suppresses Aspergillus growth
-
Reduces fungal burden
-
Helps stabilise lung disease
-
Provides systemic antifungal coverage
Clinical improvement is gradual over weeks.
2️⃣ How Long Is Treatment?
In CPA
-
Often 6–12 months or longer
-
May be used when other azoles cause side effects
-
Sometimes used as long-term suppressive therapy
In Invasive Aspergillosis
-
Duration depends on immune recovery and response
-
Often several months
In ABPA
-
Used selectively when other azoles are not tolerated
As with all azoles, stopping too early may lead to relapse.
3️⃣ Pharmacokinetics – Why It’s Different
Isavuconazole has more predictable pharmacokinetics than itraconazole or voriconazole.
Key features:
-
High oral bioavailability
-
Not dependent on gastric acidity
-
Food has minimal impact
-
Linear pharmacokinetics (dose–level relationship more predictable)
-
Long half-life (~100–130 hours)
Importantly:
It shortens the QT interval (unlike other azoles, which may prolong it).
This can make it preferable in patients with QT prolongation risk.
4️⃣ Do We Need Blood Level Monitoring?
Therapeutic Drug Monitoring (TDM) is not routinely required in all patients.
However, levels may be considered in:
-
Treatment failure
-
Drug interactions
-
Extreme body weight
-
Severe liver disease
-
Long-term therapy
This is a practical advantage compared with voriconazole.
5️⃣ Common Side Effects (Usually Mild)
-
Nausea
-
Vomiting
-
Diarrhoea
-
Headache
Generally fewer visual or skin-related effects compared with voriconazole.
6️⃣ Less Common but Important Effects
Liver Abnormalities
Routine liver monitoring is recommended.
Most abnormalities are mild and reversible.
Gastrointestinal Upset
Can occur early in therapy but often settles.
Infusion Reactions (IV Form)
Occasional mild reactions with IV administration.
Cardiac Effects
Unlike other azoles:
-
Isavuconazole may shorten QT interval
-
It is not associated with QT prolongation
This makes it attractive in patients with:
-
Existing QT prolongation
-
Multiple QT-prolonging drugs
However, ECG review may still be prudent in complex cardiac patients.
7️⃣ Drug Interactions
Isavuconazole:
-
Moderately inhibits CYP3A4
-
Has fewer interactions than some other azoles
Still review carefully, especially with:
-
Immunosuppressants
-
Statins
-
Certain anticoagulants
Avoid:
-
St John’s Wort
-
Strong enzyme inducers
Grapefruit has less impact than with other azoles but is generally avoided as a precaution.
8️⃣ Comparison Snapshot
| Feature | Itraconazole | Voriconazole | Posaconazole | Isavuconazole |
|---|---|---|---|---|
| Acid-dependent absorption | Yes (capsules) | No | No (tablet) | No |
| Genetic metabolism impact | Low | High (CYP2C19) | Low | Low |
| QT prolongation | Minimal | Possible | Possible | No (shortens QT) |
| Visual side effects | Rare | Common | Rare | Rare |
| TDM required | Yes | Essential | Recommended | Usually not |
| Long-term tolerability | Moderate | Sometimes limited | Often good | Often very good |
Balanced Summary for Patients
Isavuconazole is a newer antifungal that is often easier to tolerate and has more predictable levels in the body. Blood tests and monitoring help ensure treatment remains safe and effective.
Clinician Checklist
-
Confirm indication and prior azole exposure
-
Baseline liver function tests
-
Review interacting medications
-
Consider ECG if complex cardiac history
-
Consider TDM only if clinically indicated
Posaconazole in Aspergillosis
A balanced guide for patients and clinicians
-
Chronic pulmonary aspergillosis (CPA)
-
Allergic bronchopulmonary aspergillosis (ABPA) (selected or refractory cases)
-
Invasive aspergillosis
-
Patients intolerant of itraconazole or voriconazole
-
Antifungal prophylaxis in high-risk immunocompromised patients
It is generally well tolerated and often used when other azoles cause side effects.
1️⃣ What Posaconazole Does
Like other azoles, posaconazole blocks fungal ergosterol synthesis (CYP51 inhibition), preventing fungal growth.
It:
-
Suppresses Aspergillus replication
-
Reduces fungal burden
-
Helps stabilise lung disease in CPA
-
Can reduce steroid need in some ABPA cases
It works gradually over weeks.
2️⃣ How Long Is Treatment?
In CPA
-
Often 6–12 months or longer
-
Sometimes long-term suppressive therapy
-
Used if other azoles are ineffective or not tolerated
In ABPA
-
Used in refractory or steroid-dependent disease
In prophylaxis
-
Duration depends on immune suppression status
As with other azoles, premature discontinuation may lead to relapse.
3️⃣ Formulations Matter
Posaconazole comes in:
-
Delayed-release tablets
-
Oral suspension
-
Intravenous formulation
Tablets (preferred)
-
Good, reliable absorption
-
Less affected by food
-
More predictable levels
Oral suspension
-
Absorption highly dependent on food (especially fatty meals)
-
Greater variability
In most CPA practice, tablets are preferred.
4️⃣ Why Blood Level Monitoring Is Still Important
Posaconazole has more predictable pharmacokinetics than itraconazole or voriconazole, but monitoring is still recommended.
Reasons:
-
Interpatient variability
-
Drug interactions
-
Severe infection requires adequate exposure
-
Toxicity avoidance
If Levels Are Too Low
-
Inadequate fungal suppression
-
Ongoing disease activity
-
Risk of resistance
If Levels Are Too High
-
Liver abnormalities
-
Gastrointestinal symptoms
-
Rare cardiac effects
Typical Target (Trough)
-
1 mg/L for treatment
-
0.7 mg/L often sufficient for prophylaxis
(Laboratory guidance varies.)
Levels are typically checked:
-
After 5–7 days
-
After dose adjustments
-
If response is suboptimal
-
If toxicity suspected
5️⃣ Common Side Effects (Usually Mild)
-
Nausea
-
Diarrhoea
-
Abdominal discomfort
-
Headache
These are often less troublesome than with voriconazole.
6️⃣ Less Common but Important Effects
Liver Abnormalities
Routine monitoring required.
Most are mild and reversible.
QT Interval Prolongation
Posaconazole can prolong QT interval.
Caution in patients with:
-
Known arrhythmias
-
Electrolyte imbalance
-
Other QT-prolonging drugs
ECG monitoring may be appropriate in higher-risk individuals.
Hypertension & Mineralocorticoid Effect (Rare)
High levels can rarely cause:
-
Elevated blood pressure
-
Low potassium
More common with long-term or high exposure.
Neuropathy
Much less commonly reported than with other azoles, but peripheral symptoms should still be assessed carefully if they occur.
7️⃣ Food & Drug Advice
-
Tablets: can be taken with or without food (follow prescribing guidance)
-
Suspension: take with food (preferably fatty meal)
Avoid:
-
Grapefruit
-
St John’s Wort
Posaconazole inhibits CYP3A4 and interacts with:
-
Statins
-
Certain immunosuppressants
-
Some anticoagulants
Medication review is essential.
8️⃣ Comparison Snapshot
| Feature | Itraconazole | Voriconazole | Posaconazole |
|---|---|---|---|
| Absorption variability | High | Moderate | Low–Moderate (tablet) |
| Visual side effects | Rare | Common | Rare |
| Photosensitivity | Rare | Common | Rare |
| QT prolongation | Minimal | Possible | Possible |
| TDM needed | Yes | Essential | Recommended |
| Long-term tolerability | Moderate | Sometimes limited | Often good |
Balanced Summary for Patients
Posaconazole is a newer azole that is often well tolerated and provides reliable antifungal coverage. Blood tests help ensure the level is effective and safe. Most patients complete treatment without major difficulties.
Clinician Checklist
-
Confirm formulation (tablet preferred in CPA)
-
Baseline LFTs
-
Review ECG if cardiac risk present
-
Check electrolytes (especially potassium)
-
Arrange trough level after initiation
-
Review full medication list
Voriconazole in Aspergillosis
A balanced guide for patients and clinicians
-
Chronic pulmonary aspergillosis (CPA)
-
Allergic bronchopulmonary aspergillosis (ABPA) (selected cases)
-
Invasive aspergillosis
-
Azole-resistant or itraconazole-intolerant cases
It is available orally and intravenously and is often used when a stronger or more reliably absorbed azole is required.
1️⃣ What Voriconazole Does
Voriconazole works by blocking fungal ergosterol synthesis (CYP51 inhibition), which disrupts the fungal cell membrane.
Compared with itraconazole:
-
More potent against Aspergillus
-
More predictable oral absorption
-
More central nervous system penetration
It often produces symptom improvement over weeks, though some effects (e.g. visual symptoms) may occur quickly.
2️⃣ How Long Is Treatment?
In CPA
-
Often 6–12 months or longer
-
Sometimes used as second-line or after intolerance to itraconazole
-
Long-term suppressive therapy may be required
In ABPA
-
Used in selected steroid-dependent or refractory cases
In invasive disease
-
Typically several months depending on response and immune status
3️⃣ Why Blood Level Monitoring Is Essential
Voriconazole has non-linear pharmacokinetics.
Small dose changes can cause large blood level shifts.
Two patients on the same dose may have very different levels due to:
-
Liver metabolism (CYP2C19 genetic variation is important)
-
Drug interactions
-
Age
-
Weight
-
Liver function
If Levels Are Too Low
-
Treatment failure
-
Persistent fungal activity
-
Risk of resistance
If Levels Are Too High
-
Liver toxicity
-
Neurological side effects
-
Visual disturbances
-
Increased interaction risk
Typical Target (Trough)
-
Generally 1–5.5 mg/L (lab dependent)
-
Toxicity risk increases >5–6 mg/L
Levels are usually checked:
-
5–7 days after starting
-
After dose adjustments
-
If side effects occur
-
If clinical response is inadequate
4️⃣ Common Side Effects (Often Mild & Reversible)
Visual Disturbances (Very Common but Usually Harmless)
-
Blurred vision
-
Altered colour perception
-
Light sensitivity
-
“Wavy” vision
These typically:
-
Occur within 30–60 minutes of dosing
-
Last less than an hour
-
Reduce over time
Patients should avoid night driving initially until they understand their response.
Photosensitivity
-
Increased sensitivity to sunlight
-
Sunburn risk
-
Long-term risk of skin damage with prolonged therapy
Sun protection is important.
Gastrointestinal
-
Nausea
-
Abdominal discomfort
5️⃣ Less Common but Important Effects
Neurological
-
Headache
-
Vivid dreams
-
Hallucinations (usually at high levels)
-
Confusion (dose-related)
These are generally reversible with dose adjustment.
Liver Abnormalities
Routine liver function monitoring is required.
Most abnormalities are mild and resolve with dose modification.
Cardiac Effects
Voriconazole can prolong the QT interval.
Caution in patients with:
-
Known arrhythmias
-
Electrolyte imbalance
-
Other QT-prolonging drugs
ECG monitoring may be appropriate in higher-risk patients.
Skin Cancer Risk (Long-Term Use)
With prolonged use (especially >1–2 years):
-
Increased risk of skin squamous cell carcinoma
-
Particularly in transplant recipients
Sun protection and dermatology review are advised for long-term therapy.
6️⃣ Food & Drug Advice
-
Avoid grapefruit
-
Avoid St John’s Wort
-
Take tablets at least 1 hour before or after meals (food reduces absorption)
Voriconazole has many CYP-mediated interactions and requires careful medication review.
7️⃣ Comparison With Itraconazole (Simple Overview)
| Feature | Itraconazole | Voriconazole |
|---|---|---|
| Absorption variability | High | More predictable |
| Visual side effects | Rare | Common but mild |
| Photosensitivity | Rare | More common |
| QT prolongation | Minimal | Possible |
| TDM needed | Yes | Yes (essential) |
Balanced Summary for Patients
Voriconazole is a strong antifungal used when more reliable or potent treatment is needed. Most side effects are manageable and reversible, and blood monitoring keeps treatment safe.
Clinician Checklist
-
Confirm indication and prior azole exposure
-
Check baseline LFTs
-
Review ECG if cardiac risk present
-
Assess drug interactions (CYP2C19, 2C9, 3A4)
-
Arrange trough level at day 5–7
-
Counsel regarding visual symptoms and sun protection
🧬 How Biologics Are Reshaping Our Understanding of ABPA Subtypes
For many years, Allergic Bronchopulmonary Aspergillosis (ABPA) was viewed as a single condition:
An allergic reaction to Aspergillus fumigatus in the lungs, treated primarily with steroids and sometimes antifungal medication.
Biologic therapies are changing that picture.
They are not just new treatments — they are helping us understand that ABPA may not be one uniform disease, but a spectrum of related inflammatory patterns.
🧠 The Traditional View of ABPA
Historically, ABPA has been defined by:
-
Asthma (or cystic fibrosis)
-
High total IgE
-
Sensitisation to Aspergillus
-
Raised eosinophils
-
Characteristic CT changes (e.g. bronchiectasis, mucus plugging)
The dominant biological explanation was:
A Type 2 (allergic) immune overreaction driven by eosinophils and IgE.
Steroids were used to suppress this immune response.
This model assumed that most patients had broadly similar immune drivers.
💊 What Are Biologics?
Biologics are targeted antibody therapies designed to block specific immune pathways.
In asthma and ABPA, the main targets are:
-
IL-5 (drives eosinophils)
-
IL-5 receptor
-
IL-4 / IL-13 (drive allergic inflammation)
-
IgE
Examples include:
-
Anti–IL-5 therapies (e.g. mepolizumab, benralizumab)
-
Anti–IL-4/IL-13 therapy (e.g. dupilumab)
-
Anti-IgE therapy (e.g. omalizumab)
Instead of broadly suppressing immunity like steroids, they selectively block parts of the allergic pathway.
🔍 What Biologics Are Teaching Us
As biologics have been used in ABPA (often off-label or in specialist centres), an interesting pattern has emerged:
Not all ABPA behaves the same way.
Some patients respond dramatically to anti–IL-5 therapy.
Others respond better to anti–IL-4/IL-13 therapy.
Some show strong IgE-driven disease.
Others appear more mucus-dominant.
This suggests that ABPA may include different inflammatory endotypes (biological subtypes), even if outward symptoms look similar.
🧩 Possible Emerging ABPA Subtypes
While research is ongoing, clinicians are beginning to recognise patterns such as:
1️⃣ Strongly Eosinophilic-Dominant ABPA
-
Very high eosinophils
-
Frequent exacerbations
-
Often responds well to IL-5 blockade
2️⃣ IgE-Heavy Allergic ABPA
-
Extremely high total IgE
-
Prominent allergic features
-
May respond to anti-IgE therapy
3️⃣ Mucus-Plug Dominant ABPA
-
Recurrent thick mucus impaction
-
Radiological plugging
-
May involve additional inflammatory drivers
4️⃣ Steroid-Dependent ABPA
-
Relapses when steroids reduced
-
Biologics may allow steroid-sparing strategies
These patterns are not yet formal categories, but biologics are revealing that ABPA is biologically more complex than once thought.
🧪 Blood Eosinophils vs Airway Inflammation
Biologics have also highlighted another key insight:
Blood eosinophil levels do not always perfectly reflect what is happening in the lungs.
Some patients:
-
Have modest blood eosinophils
-
But still show eosinophilic airway activity
Biologic response patterns are helping refine how we interpret these markers.
🧠 Moving From “Diagnosis” to “Endotype”
Traditionally, medicine focused on:
Diagnosis (ABPA vs not ABPA)
Biologics are pushing us toward:
Endotype (which immune pathway is dominant in this patient?)
This matters because targeted therapy works best when matched to the dominant pathway.
In future, ABPA may be classified not just by clinical features, but by molecular drivers.
🫁 What This Means for Patients
Biologics offer:
-
Reduced steroid dependence
-
Fewer exacerbations
-
Improved lung function in selected patients
-
Potential improvement in mucus burden
But they also help answer deeper questions:
-
Why do some patients relapse frequently?
-
Why do some have extreme eosinophilia?
-
Why do others have more mucus plugging than inflammation?
They are helping personalise ABPA care.
⚖ Important Caveats
-
Biologics are not currently licensed specifically for ABPA in many countries.
-
Evidence is growing but still developing.
-
They are usually considered in specialist centres.
-
They are not appropriate for every patient.
Steroids and antifungals remain core treatments.
🔭 The Future
Over the next decade, we may see:
-
Better classification of ABPA subtypes
-
Biomarker-guided treatment selection
-
Reduced long-term steroid exposure
-
Improved understanding of mucus plug biology
-
Trials specifically designed for ABPA (rather than extrapolated from asthma)
Biologics are not just new drugs.
They are acting as scientific tools that are reshaping how we think about ABPA itself.
🧠 Key Takeaway
ABPA is no longer seen as one single uniform allergic condition.
Biologic therapies are revealing that:
ABPA is likely a spectrum of related inflammatory patterns — and treatment may increasingly be tailored to the dominant pathway in each individual.
References
Agarwal R, Sehgal IS, Muthu V, Denning DW, Chakrabarti A, Soundappan K, Garg M, Rudramurthy SM, Dhooria S, Armstrong-James D, Asano K, Gangneux JP, Chotirmall SH, Salzer HJF, Chalmers JD, Godet C, Joest M, Page I, Nair P, Arjun P, Dhar R, Jat KR, Joe G, Krishnaswamy UM, Mathew JL, Maturu VN, Mohan A, Nath A, Patel D, Savio J, Saxena P, Soman R, Thangakunam B, Baxter CG, Bongomin F, Calhoun WJ, Cornely OA, Douglass JA, Kosmidis C, Meis JF, Moss R, Pasqualotto AC, Seidel D, Sprute R, Prasad KT, Aggarwal AN. Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses. Eur Respir J. 2024 Apr 4;63(4):2400061. doi: 10.1183/13993003.00061-2024. PMID: 38423624; PMCID: PMC10991853.
🔬 Charcot–Leyden Crystals in ABPA and Asthma
What are they? Why do they form? Do they matter?
If you live with Allergic Bronchopulmonary Aspergillosis (ABPA) or severe asthma, you may see the term Charcot–Leyden crystals in a sputum or pathology report.
They can sound worrying.
They are:
-
Not fungus
-
Not infection
-
Not cancer
They are a sign of a particular type of allergic inflammation in the airways.
🧬 What Are Charcot–Leyden Crystals?
Charcot–Leyden crystals are microscopic, needle-shaped structures found in mucus.
They are made from a protein called galectin-10, which is stored inside a type of white blood cell called an eosinophil.
Eosinophils are immune cells involved in:
-
Allergic asthma
-
ABPA
-
Severe asthma with fungal sensitisation
-
Parasitic infections
When eosinophils are activated and break down, they release galectin-10.
If enough of this protein accumulates in thick airway mucus, it crystallises into visible crystals.
So the crystals are made from your immune cells, not from Aspergillus.
🫁 Why Do They Appear in ABPA?
In ABPA:
-
The immune system overreacts to Aspergillus fumigatus.
-
This triggers a strong allergic (Type 2) immune response.
-
Large numbers of eosinophils move into the airways.
-
Eosinophils break down and release galectin-10.
-
The protein crystallises inside mucus plugs.
The crystals are therefore a footprint of intense allergic inflammation, not fungal invasion.
🌡 Is Most ABPA Eosinophilic?
Yes — almost all classical ABPA is eosinophilic.
ABPA is fundamentally a Type 2 allergic condition, driven by immune pathways involving:
-
IL-4
-
IL-5
-
IL-13
-
IgE
-
Eosinophils
IL-5 in particular stimulates eosinophil production and survival.
Because of this, eosinophils are central to the disease process.
Historically, raised blood eosinophils have been part of diagnostic criteria.
However:
-
Eosinophil counts can fluctuate
-
Steroids can suppress blood levels
-
Eosinophils may still be present in airway mucus even if blood counts appear normal
So ABPA is biologically eosinophilic — even if a single blood test does not show a high count.
True non-eosinophilic ABPA would be unusual and would prompt clinicians to reconsider the diagnosis.
❓ Are Crystals Caused by Aspergillus Infection?
No.
They are caused by the immune reaction to Aspergillus — not by the fungus itself.
They can also be seen in:
-
Severe eosinophilic asthma
-
Parasitic infections
-
Other allergic lung conditions
They reflect eosinophil activity, not fungal growth.
🧠 Why Don’t All People with Asthma Develop These Crystals?
Asthma is not one single disease. It has different inflammatory patterns.
Type 2 (Eosinophilic) Asthma
This involves high eosinophils and allergic pathways.
Common in:
-
Allergic asthma
-
ABPA
-
Severe eosinophilic asthma
These patients can develop Charcot–Leyden crystals.
Non–Type 2 (Non-Eosinophilic) Asthma
This includes:
Neutrophilic asthma
Driven by neutrophils rather than eosinophils.
Paucigranulocytic asthma
Very few inflammatory cells present.
In these forms:
-
Eosinophils are low
-
Galectin-10 is not released in large amounts
-
Crystals are unlikely to form
🧱 Do Charcot–Leyden Crystals Make Mucus Plugs Worse?
Possibly.
Research suggests they may:
-
Increase mucus thickness
-
Contribute mechanically to airway blockage
-
Stimulate further inflammation
For many years they were thought to be harmless debris.
Modern studies suggest they may actively amplify inflammation when present in large amounts.
🎯 Do They Have a Purpose?
Eosinophils evolved mainly to help fight parasitic infections.
Galectin-10 probably has immune signalling roles inside cells.
However, when large amounts are released into thick airway mucus, crystallisation appears to be a by-product of excessive immune activity rather than a useful defence.
In ABPA and allergic asthma, they are more likely part of the problem than part of the solution.
💧 Can Their Formation Be Reduced?
Hydration alone does not stop them forming.
Drinking fluids helps:
-
Keep mucus less sticky
-
Support airway clearance
But it does not prevent eosinophils releasing galectin-10.
What reduces crystal formation?
Reducing eosinophilic inflammation:
-
Corticosteroids
-
Anti-IL-5 biologics
-
Anti-IL-4/IL-13 biologics
When eosinophil numbers fall:
→ Less galectin-10 is released
→ Fewer crystals form
Antifungal treatment in ABPA may indirectly help by reducing allergic stimulation, but the main driver is the immune response.
📊 Do They Change Treatment?
Not directly.
Doctors base treatment on:
-
Symptoms
-
Blood eosinophils
-
Total IgE
-
Imaging
-
Lung function
-
Exacerbation history
Crystals support the diagnosis of eosinophilic inflammation but do not determine treatment alone.
🔎 What Do They Tell Us?
Charcot–Leyden crystals tell us:
-
The airway inflammation is eosinophilic.
-
The immune response is strongly allergic.
-
Mucus plugging risk may be higher.
They are a marker of immune overreaction, not infection severity.
🧠 Key Points to Remember
-
They are made from proteins released by eosinophils.
-
They are not Aspergillus.
-
They do not mean invasive fungal infection.
-
Most classical ABPA is eosinophilic.
-
They are unlikely in non-eosinophilic asthma.
-
Reducing eosinophils reduces their formation.
-
Hydration helps clearance but does not prevent formation.
In simple terms:
Charcot–Leyden crystals are microscopic signs that the immune system is working too hard in the airways.
Aspergillosis, immunity, and risk
Primary immune deficiencies and immune modifiers explained
A single, comprehensive explainer for expert patients, carers, and non-specialists
Why this article exists
Aspergillus is a mould that everyone breathes in every day. Most people clear it without difficulty.
A small number of people develop aspergillosis because the balance between the fungus, the lungs, and the immune system is disturbed.
This article explains:
-
Rare primary (inherited) immune deficiencies that are clearly linked to aspergillosis
-
Common immune “modifier” factors that can increase risk or severity but do not cause disease on their own
-
How these factors stack together in real life
Key reassurance up front
There are 500+ recognised primary immune deficiencies
Only ~20–30 are clearly linked to aspergillosis
Most people with aspergillosis do not have any inherited immune disorder
The unifying concept: three immune pathways to aspergillosis
Almost all immune–aspergillus relationships fall into three mechanisms. Understanding these matters more than memorising names.
1. Reduced ability to kill the fungus
Some immune cells fail to destroy Aspergillus spores effectively.
→ Risk of invasive aspergillosis, sometimes severe or life-threatening.
2. Lung damage over time
Repeated infections or inflammation damage airways or leave cavities.
→ Risk of chronic pulmonary aspergillosis (CPA) or aspergillomas.
3. Excessive allergic inflammation
The immune system over-reacts to Aspergillus rather than failing to fight it.
→ Allergic bronchopulmonary aspergillosis (ABPA) and severe fungal-sensitised asthma.
Many conditions overlap more than one pathway.
Section 1: Primary (inherited) immune deficiencies clearly linked to aspergillosis
Rare, high-impact, and sometimes life-changing when present
These are the conditions clinicians usually mean when they talk about “immune causes of aspergillus disease”.
A. Phagocyte defects
Strongest association with invasive aspergillosis
-
Chronic granulomatous disease (CGD)
-
Autosomal recessive forms of CGD
-
Severe congenital neutropenia
-
Cyclic neutropenia
-
Leukocyte adhesion deficiency type I
Typical pattern
-
Aspergillosis at a young age
-
Invasive lung disease ± spread beyond lungs
-
Often no other obvious risk factors
B. Hyper-IgE and severe allergy syndromes
Allergic, chronic, and cavity-associated disease
-
STAT3 hyper-IgE syndrome
-
DOCK8 deficiency
-
PGM3 deficiency
-
ZNF341 deficiency
-
IL6ST deficiency
Typical pattern
-
Severe asthma and allergy
-
Thick mucus, recurrent infections
-
ABPA, later CPA or aspergillomas
C. Combined immunodeficiencies
Immune coordination problems
-
Severe combined immunodeficiency (milder or surviving forms)
-
Omenn syndrome
-
ZAP-70 deficiency
-
Major histocompatibility complex class II deficiency
-
CD40 ligand deficiency (hyper-IgM syndrome)
Typical pattern
-
Broad infection susceptibility
-
Aspergillosis can behave aggressively
D. Defects of fungal recognition and innate signalling
Often dramatic or unexpected presentations
-
CARD9 deficiency
-
Dectin-1 (CLEC7A) complete deficiency
-
MALT1 deficiency
Typical pattern
-
Severe or unusual aspergillosis
-
Lung, brain, or deep tissue involvement
-
Sometimes first presents in adulthood
E. Immune dysregulation syndromes
Mixed infection, inflammation, and autoimmunity
-
CTLA-4 haploinsufficiency
-
LRBA deficiency
-
STAT1 gain-of-function mutations
-
IPEX syndrome (FOXP3 deficiency)
Typical pattern
-
Inflammatory lung disease
-
Chronic or invasive aspergillosis emerging over time
F. Antibody deficiencies (indirect risk via lung damage)
-
Common variable immunodeficiency
-
X-linked agammaglobulinaemia
-
Activated PI3K-delta syndrome
Important nuance
Antibodies do not normally kill Aspergillus.
Risk arises after years of lung damage, not early in life.
Section 2: Immune modifier-types that can amplify risk
Common, low-penetrance, and often invisible on routine testing
These are not immune deficiencies, but they can influence who struggles, how severely, and why disease persists.
Mannose-binding lectin (MBL) deficiency
-
Common (≈5–10% of population)
-
Affects fungal recognition and complement activation
-
Usually mild on its own
-
Becomes relevant with lung disease, steroids, or other immune issues
Partial fungal-recognition receptor variants
-
Heterozygous dectin-1 variants
-
Toll-like receptor polymorphisms (for example TLR2, TLR4)
Effect
-
Slower fungal recognition
-
Increased colonisation or allergic response
-
Act as risk amplifiers, not causes
Cytokine balance variants
Small genetic differences affecting immune “signal strength”, including:
-
Interleukin-6
-
Interleukin-10
-
Tumour necrosis factor-alpha
These modify:
-
Inflammation intensity
-
Tissue damage vs clearance balance
Allergy-biased (Th2-skewed) immunity
Not a disease, but a recognised immune tendency.
Features:
-
Asthma
-
Eczema
-
Nasal polyps
-
High immunoglobulin E levels
-
Eosinophilia
Strongly associated with:
-
Fungal sensitisation
-
ABPA
-
Difficult-to-control asthma
Impaired mucociliary clearance
A functional immune–mechanical issue.
Seen in:
-
Severe asthma
-
Bronchiectasis
-
Chronic sinus disease
Effect:
-
Aspergillus spores are not physically cleared
-
Prolonged immune exposure
-
Increased colonisation and allergy
Age-related immune change (immunosenescence)
-
Normal reduction in immune speed and coordination with age
-
Particularly relevant to chronic pulmonary aspergillosis
Not a disease, but an important modifier of outcome.
Airway epithelial vulnerability
Subtle weaknesses in:
-
Airway lining integrity
-
Antimicrobial peptide production
-
Local immune signalling
Can increase:
-
Fungal adherence
-
Chronic colonisation
-
Allergic sensitisation
Section 3: Risk stacking – how this works in real life
Aspergillosis rarely results from one single factor.
Instead, several modest risks align:
-
Mild MBL deficiency
-
Severe asthma
-
Corticosteroid exposure
-
Bronchiectasis
-
Age-related immune change
→ Together, they create real disease risk, even though none alone would.
This explains why:
-
Two people with similar scans can behave very differently
-
One patient relapses while another stabilises
-
“Why me?” often has no single answer
Section 4: When clinicians investigate immune causes
Testing is targeted, not routine. It is usually considered when there is:
-
Aspergillosis at a young age
-
Invasive or unusually severe disease
-
Disease without classic risk factors
-
Recurrent infections plus severe asthma or allergy
-
A family history of unusual infections
Section 5: Why identifying (or excluding) immune factors helps
Understanding immune contribution can:
-
Explain disease pattern and behaviour
-
Guide antifungal choice and duration
-
Inform long-term prevention strategies
-
Reduce future lung damage
-
Reassure patients when no immune defect is found
Key take-home messages
-
Aspergillus exposure is universal; immune causes are rare
-
Only ~20–30 inherited immune deficiencies are clearly linked to aspergillosis
-
Modifier-type immune factors are common and usually harmless alone
-
Aspergillosis often reflects risk stacking, not a single diagnosis
-
Understanding patterns matters more than labels
-
Specialist care improves precision and outcomes